Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid

BACKGROUND: Outcomes involving newer direct-acting antiviral (DAA) hepatitis C virus (HCV) regimens have not been studied extensively among the Medicaid population. OBJECTIVE: To assess clinical (treatment failure) and economic outcomes for chronic HCV-infected Oklahoma Medicaid members following tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Timothy T., Keast, Shellie L., Farmer, Kevin C., Thompson, David M., Rathbun, R. Chris, Nesser, Nancy J., Holderread, Bethany P., Skrepnek, Grant H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398076/
https://www.ncbi.nlm.nih.gov/pubmed/29952711
http://dx.doi.org/10.18553/jmcp.2018.24.7.664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398076/
https://www.ncbi.nlm.nih.gov/pubmed/29952711
http://dx.doi.org/10.18553/jmcp.2018.24.7.664

Ejemplares similares